Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis, from binding to its heterodimeric receptor. In the phase 2b PATHWAY study, tezepelumab significantly reduced annualized asthma exacerbation rates...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Asthma Allergy
मुख्य लेखकों: Emson, Claire, Corren, Jonathan, Sałapa, Kinga, Hellqvist, Åsa, Parnes, Jane R, Colice, Gene
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove 2021
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7868291/
https://ncbi.nlm.nih.gov/pubmed/33568920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S288260
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन